Cytokinetics Ownership | Who Owns Cytokinetics?

Overview Forecast RevenueFinancials Chart Transcripts

Cytokinetics Ownership Summary

Cytokinetics is owned by 115.50% institutional investors, 0.70% insiders. T. rowe price investment management is the largest institutional shareholder, holding 14.74% of CYTK shares. Vanguard Health Care Inv is the top mutual fund, with 3.41% of its assets in Cytokinetics shares.

CYTK Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Cytokinetics	115.50%	0.70%	-16.20%
Sector	Healthcare Stocks	492.67%	11.09%	-403.76%
Industry	Biotech Stocks	295.31%	11.22%	-206.53%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
T. rowe price investment management	17.60M	14.74%	$581.59M
Blackrock	14.67M	14.40%	$794.97M
Blackrock funding, inc. /de	15.53M	13.00%	$853.30M
Fmr	13.09M	10.96%	$719.52M
Vanguard group	11.86M	9.93%	$651.65M
Wellington management group llp	7.89M	6.70%	$371.08M
State street	6.17M	5.24%	$290.11M
Deep track capital, lp	3.65M	3.06%	$120.60M
Geode capital management	3.04M	2.54%	$167.11M
Vestal point capital, lp	2.98M	2.49%	$98.29M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Rp management	980.39K	22.73%	$51.76M
Sarissa capital management lp	588.36K	12.59%	$19.44M
Rosalind advisors	400.00K	7.51%	$21.98M
Melqart asset management (uk)	1.33M	6.26%	$43.83M
Boxer capital	2.10M	5.99%	$113.78M
Vestal point capital, lp	2.98M	5.18%	$98.29M
Nationale-nederlanden powszechne towarzystwo emerytalne	1.19M	5.06%	$65.54M
Deep track capital, lp	3.65M	3.87%	$120.60M
Dafna capital management	398.10K	3.63%	$13.15M
Great point partners	150.00K	3.22%	$4.96M

Top Buyers

Holder	Shares	% Assets	Change
T. rowe price investment management	17.60M	0.37%	7.65M
Blackrock	14.67M	0.02%	2.26M
Fmr	13.09M	0.04%	1.82M
Norges bank	989.72K	0.01%	989.72K
Deep track capital, lp	3.65M	3.87%	576.15K

Top Sellers

Holder	Shares	% Assets	Change
Darwin global management	-	-	-4.58M
Pfm health sciences, lp	-	-	-1.76M
Point72 asset management	-	-	-1.72M
Westfield capital management co lp	-	-	-1.31M
Ubs group	1.80M	0.02%	-1.27M

New Positions

Holder	Shares	% Assets	Change	Value
Norges bank	989.72K	0.01%	989.72K	$46.56M
Frazier life sciences management	554.73K	0.73%	554.73K	$18.33M
Affinity asset advisors	350.00K	1.68%	350.00K	$19.24M
Susquehanna portfolio strategies	264.33K	0.19%	264.33K	$8.73M
Silverarc capital management	211.00K	1.56%	211.00K	$11.60M

Sold Out

Holder	Change
New england capital financial advisors	-1.00
Financial gravity asset management	-2.00
Ameritas advisory services	-4.00
American capital advisory	-5.00
Institutional & family asset management	-7.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	344	-10.88%	137,969,518	1.88%	115	0.88%	171	-14.50%	106	-0.93%
Mar 31, 2025	25	-93.40%	16,158,180	-87.73%	13	0.11%	15	-91.28%	5	-96.09%
Dec 31, 2024	374	-5.32%	131,318,059	-2.91%	111	0.84%	166	-12.17%	128	29.29%
Sep 30, 2024	390	0.52%	135,010,879	-0.29%	114	0.65%	187	-6.50%	99	-2.94%
Jun 30, 2024	388	-14.35%	135,400,422	16.07%	132	1.01%	200	-11.11%	102	-22.14%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Health Care Inv	4.07M	3.41%	-
iShares Core S&P Mid-Cap ETF	3.89M	3.25%	-
Vanguard US Total Market Shares ETF	3.75M	3.15%	128.42K
Vanguard Total Stock Mkt Idx Inv	3.72M	3.11%	-77.64K
Vanguard Small Cap Index	2.90M	2.42%	-19.00K
iShares Russell 2000 ETF	2.81M	2.35%	-
T. Rowe Price Mid-Cap Growth	2.50M	2.09%	245.40K
T. Rowe Price Capital Appreciation	2.44M	2.04%	-556.00
T. Rowe Price US Mid-Cap Growth Equity	2.25M	1.88%	267.30K
T. Rowe Price Small-Cap Value	2.10M	1.75%	-4.81K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Nov 11, 2025	Kaye Edward M. MD	-	Sell	$336.79K
Nov 04, 2025	Malik Fady Ibraham	EVP Research & Development	Sell	$136.67K
Oct 30, 2025	Blum Robert I	President & CEO	Sell	$314.30K
Oct 27, 2025	WIERENGA WENDELL	-	Sell	$256.73K
Oct 21, 2025	Malik Fady Ibraham	EVP Research & Development	Sell	$122.55K

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	9
2025 Q3	-	15
2025 Q2	-	19
2025 Q1	-	22
2024 Q4	-	20

CYTK Ownership FAQ

Who Owns Cytokinetics?

Cytokinetics shareholders are primarily institutional investors at 115.50%, followed by 0.70% insiders and -16.20% retail investors. The average institutional ownership in Cytokinetics's industry, Biotech Stocks , is 295.31%, which Cytokinetics falls below.

Who owns the most shares of Cytokinetics?

Cytokinetics’s largest shareholders are T. rowe price investment management (17.6M shares, 14.74%), Blackrock (14.67M shares, 14.40%), and Blackrock funding, inc. /de (15.53M shares, 13.00%). Together, they hold 42.13% of Cytokinetics’s total shares outstanding.

Does Blackrock own Cytokinetics?

Yes, BlackRock owns 14.40% of Cytokinetics, totaling 14.67M shares as of Jun 2024. This represents 0.02% of BlackRock's total assets, with a market value of 794.97M$. In the last quarter, BlackRock increased its holdings by 2.26M shares, a 18.19% change.

Who is Cytokinetics’s biggest shareholder by percentage of total assets invested?

Rp management is Cytokinetics’s biggest shareholder by percentage of total assets invested, with 22.73% of its assets in 980.39K Cytokinetics shares, valued at 51.76M$.

Who is the top mutual fund holder of Cytokinetics shares?

Vanguard Health Care Inv is the top mutual fund holder of Cytokinetics shares, with 3.41% of its total shares outstanding invested in 4.07M Cytokinetics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools